Rational design of a flavivirus vaccine through abolishing viral RNA 2′-O methylation

Shi-Hua Li, Hongping Dong, Xiao-Feng Li, Xuping Xie, Hui Zhao, Yong-Qiang Deng, Xiao-Yu Wang, Qing Ye, Shun-Ya Zhu, Hong-Jiang Wang, Bo Zhang, Qi-Bin Leng, Roland Zuest, E-De Qin, Cheng-Feng Qin, and Pei-Yong Shi

Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China; a State Key Laboratory of Pathogen and Biosecurity, Beijing 100071, China; b Novartis Institute for Tropical Diseases, Singapore; c Center for Biomaterials and Biopathways, Department of Chemistry, Zhejiang University, Hangzhou 310027, China; d State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan 430071, China; e Shanghai Institute for Pasteur, Chinese Academy of Science, Shanghai, China; f Singapore Immunology Network, ASTAR (Agency for Science, Technology and Research), Singapore

† These authors contributed equally to this work.

*Corresponding authors.

C.F. Qin: Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China, Email: qin@bmi.ac.cn
Running title: Design a flavivirus vaccine through 2'-O methylation
ABSTRACT

Viruses that replicate in the cytoplasm cannot access to the host nuclear capping machinery. These viruses have evolved viral methyltransferase(s) to methylate N-7 and 2'-O cap of their RNA; alternatively, they ‘snatch’ host mRNA cap to form the 5'-end of viral RNA. The function of 2'-O methylation of viral RNA cap is to mimic cellular mRNA and to evade host innate immune restriction. A cytoplasmic virus defective in 2'-O methylation is replicative; but its viral RNA lacks 2'-O methylation, and is recognized and eliminated by host immune response. Such mutant virus could be rationally designed as a live attenuated vaccine. Here we use Japanese encephalitis virus (JEV), an important mosquito-borne flavivirus, to prove this novel vaccine concept. We show that JEV methyltransferase is responsible for both N7 and 2'-O cap methylations as well as evasion of host innate immune response. Recombinant virus completely defective in 2'-O methylation was stable in cell culture after passaging for >30 days. The mutant virus was attenuated in mice, elicited robust humoral and cellular immune response, and retained the engineered mutation in vivo. A single dose of immunization induced full protection against lethal challenge with JEV strains in mice. Mechanistically, the attenuation phenotype was attributed to the enhanced sensitivity of the mutant virus to the antiviral effects of interferon and IFIT proteins. Collectively, the results demonstrate the feasibility of using 2'-O methylation-defective virus as a vaccine approach; this vaccine approach should be applicable to other flaviviruses and non-flaviviruses that encode their own viral 2'-O methyltransferases.
INTRODUCTION

Live-attenuated vaccine represents the best medical intervention to prevent many viral diseases, such as vaccinia virus, poliovirus (Sabin), yellow fever virus (YF-17D), Japanese encephalitis virus (JEV SA14-14-2), and MMR (measles, mumps, and rubella viruses). The attenuated vaccine replicates to a low level, but induces immune response and memory that are sufficient to prevent virulent virus infection. The traditional method to develop an attenuated vaccine is via passaging the virus through a foreign host (e.g., tissue culture or live animals). The attenuation of a vaccine strain is empirically achieved through accumulation of random mutations during passaging while maintaining immunogenicity. The function of each accumulated mutations in the vaccine strain needs to be analysed to understand the mechanism of attenuation. As an alternative approach for vaccine development, viral attenuation could be rationally designed by altering the ability of virus to antagonize innate immunity (26). Such rationally designed virus is replicative and induces protective immunity; however, the virus is quickly eliminated due to its enhanced sensitivity to the antiviral effect of the host innate immune response.

RNA and DNA viruses that replicate in the cytoplasm cannot use the cellular nuclear capping machinery, and thus have evolved viral methyltransferase (MTase) to facilitate N-7 and 2'-O capping or mechanism to ‘snatch” the cap from cellular mRNA (13). We and others recently demonstrated that the 2'-O methylation of the 5' cap of viral RNA functions to subvert host innate antiviral responses through escape of IFIT-mediated suppression (5, 34). 2'-O MTase-defective West Nile virus (WNV; flavivirus), vaccinia
virus (poxvirus), and mouse hepatitis virus (MHV; coronavirus) are more sensitive to the antiviral effects of murine IFIT-2 (5). The infections of wild-type (WT) and 2'-O MTase mutant WNV induce equivalent levels of type I interferon (5). In contrast, the 2'-O MTase mutant MHV induced higher level of interferon expression than the WT MHV (34). These results prompted us to test the hypothesis of using 2'-O methylation-defective virus as a live attenuated vaccine.

Japanese encephalitis virus (JEV) belongs to the genus Flavivirus in the family of Flaviviridae. Besides JEV, many flaviviruses are significant human pathogens, including the four serotypes of dengue virus (DENV-1 to -4), West Nile virus (WNV), Yellow fever virus (YFV), and tick-borne encephalitis virus (TBEV). Flavivirus has a single-stranded, positive-sense RNA genome of approximately 11 kb in length. The genomic RNA contains a single long open reading frame (ORF) flanked by the 5' and 3' untranslated regions (UTRs). The ORF encodes three structural proteins (capsid [C], pre-membrane [prM], and envelope [E]) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The 5'-end of all flavivirus genomic RNA has a type I cap structure (m^7GpppAmp). The MTase domain, located at the N-terminus of NS5, catalyzes the N-7 and 2'-O methylations of the 5' cap (10, 25, 33) as well as internal RNA methylation (8). All these methylations use S-adenosyl-L-methionine (SAM) as a methyl donor and generate S-adenosyl-L-homocysteine (SAH) as a by-product (4). The K-D-K-E motif, conserved among all flavivirus MTases, forms the active site of the 2'-O cap and internal adenosine methylation activities (9, 10, 25).

In this study, we used JEV as a model to rationally design an attenuated virus through...
abolishing the 2'-O methylation of viral RNA. We demonstrate that, like other flaviviruses, the MTase domain of JEV performs both N-7 and 2'-O cap methylations. A mutant JEV completely defective in 2'-O methylation was more sensitive to IFN inhibition than the WT virus, thus became attenuated in mice. A single dose administration of the 2'-O-MTase mutant virus induced robust humoral and cellular immune responses, and provided full protection against lethal JEV challenge of different genotypes.

MATERIALS AND METHODS

Cells and viruses. Mammalian cell lines BHK-21, HEK293, A549, and Vero were maintained at 37°C in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS). Mosquito C6/36 cells were grown at 28°C in RPMI 1640 medium containing 5% FBS. JEV strain SA14 and SX-06, representative strain of genotype III and I (22), were prepared in mice brain and titrated in BHK-21 cells by standard plaque forming assay (7).

Expression and purification of JEV MTase domain. Recombinant MTase representing the N-terminal 300 amino acids of NS5 derived from the JEV strain AJE70 was expressed and purified from Escherichia coli Rosetta 2(DE3) pLysS cells as modified from Ray et al (25). Briefly, DNA fragment representing MTase domain was PCR amplified from JEV strain genome and cloned into an expression plasmid pET28 (a) at NdeI and XhoI sites, a his-tag was added at the N terminus. The E218 was
mutated with alanine (E218A) using QuikChange II XL site-directed mutagenesis kit (Stratagene). The E. coli cells were grown at 37°C till the optical density at 600 nm (OD_{600}), then induced by 0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 16°C for 18h. The cells were pelleted at 5,000 rpm for 15 min, resuspended and sonicated in lysis buffer (25 mM HEPES, pH 7.5, 500 mM NaCl, and 10% glycerol) plus 2 mM β-mercaptoethanol. After centrifugation at 20,000 rpm for 60 min, the lysate supernatant was loaded onto a nickel-nitrilotriacetic acid column for affinity purification. Bound protein was eluted with a lysis buffer containing 200 mM imidazole, dialyzed against the lysis buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The purified protein was concentrated, and stored at -80°C before use.

**Methylation Assay.** The RNA substrate representing the first 190 nucleotides of 5'-end of JEV genome was used for MTase assay. In vitro RNA transcription and the RNA capping were carried out as described previously (9). The 33P-labeled m7G*pppA and G*pppA-RNA (the asterisk indicates that the following phosphate is labeled) were used for N-7 and 2'-O methylations, respectively. N-7 methylation was performed in 20 μl volume in the presence of ~4 pmol of G*pppA- RNA substrate, 50 μM unlabeled SAM (New England Biolabs), and 1 μg of MTase in 50 mM Bis-Tris buffer (pH 6.0) with 2 mM dithiothreitol (DTT) and 300 mM NaCl at 30°C for 1 h. 2'-O methylation was performed in a total volume of 20 μl in buffer containing 50 mM Tris-HCl (pH 9.0), 2 mM DTT, 1 mM MgCl₂, 50 μM SAM, 3–4 pmol of m7G*pppA-RNA, and 1 μg of MTase protein. The reaction mixture was incubated at 23°C for
15-30 min. All the reactions were ended by phenol-chloroform extraction followed by ethanol precipitation. The methylated RNA products were resuspended in RNase-free H2O, digested with nuclease P1 (US Biological [Catalog number N7000] and Sigma-Aldrich [Catalog number N8630]) and analyzed on polyethyleneimine cellulose thin-layer chromatography (TLC) plates (JT Baker) using a solvent of 0.65 M LiCl. The radioactive cap structure on TLC plates was quantified by a PhosphorImager.

Construction and recovery of JEV MTase mutant (E218A). A single E218A mutation in NS5 was introduced into the infectious JEV cDNA clone (pAJE70) by PCR-based site-directed mutagenesis to produce the MTase mutant virus as previously described (29). The positive clones were finally sequenced to confirm the designed mutations and designated as pAJE70-E218A. The constructed plasmids were linearized by XhoI and treated with Mung Bean Nuclease (NEB), then subjected to in vitro transcription by using the Ribo Max™ Large Scale RNA Production system (Promega) in the presence of the m7G(5’)ppp(5’)G cap analog (Promega). RNA transcripts from pAJE70 and pAJE70-E218A were then transfected into BHK-21 cells with Lipofectamine 2000 (Invitrogen), and rescued viruses (WT and E218A) were harvested 3-4 days after transfection and subjected to following assays.

Characterization of JEV MTase mutant. Indirect immunofluorescence assay (IFA) was performed to characterize the expression of JEV E protein in BHK-21 cells transfected with equal amounts of RNA transcripts. Briefly, the transfected BHK-21 cells were fixed with cold acetone and incubated with the mouse monoclonal antibody (mAb) 4D5 specific for JEV E protein (17) following by goat anti-mouse IgG-FITC.
conjugate as previously described (7). Mutant viruses recovered from viral RNA-transfected cells (passage 0), as well as the viruses after passaged on Vero cells for 5 (passage 5) and 10 (passage 10) rounds were analysed by plaque assays as previously described (7). One-step growth curves of the WT and E218A viruses in BHK-21, Vero, and C6/36 cells were analysed as previously described (29). Briefly, cells were pre-seeded into 48-well plates and then infected with WT and E218A at a multiplicity of infection (MOI) of 1. Culture supernatants were collected at 24, 48, 72 and 96 h post infection and the titers were determined by plaque assays.

**Mouse neuroinvasiveness and neurovirulence tests.** For neuroinvasiveness tests, groups of 3-week-old female BALB/c mice (n=6) were intraperitoneally (i.p.) injected with 4×10^7 plaque forming units (PFU) of WT or E218A, respectively. For neurovirulence tests, groups of mice (n=8) were intracranially (i.c.) injected with WT or mutant viruses with serially 10-fold dilutions from 8×10^7 PFU to 8 PFU. The mortality was then monitored daily for 2 weeks. The 50% lethal dose (LD50) and average survival time (AST) were calculated as previously described (16). All the animal experimental procedures were approved by and carried out in accordance with the guidelines of the Animal Experiment Committee of State Key Laboratory of Pathogen and Biosecurity, China.

**Viremia and tissue distribution.** At least three of the infected mice were bled periorbitally and dissected at 1, 3, 5 and 7 days post infection. Brains, spinal cord, livers, spleens and kidneys of mice were collected, homogenized, and diluted with PBS to make the final 10% (w/v) suspensions. The viremia and organ distribution of JEV were
measured by plaque assay on BHK-21 cells. Student’s t-test was used to determine whether a significant difference (P<0.05) existed.

**Immunization and challenge experiments in mice.** Groups of 4-week-old female BALB/c mice (n=10) were subcutaneously (s.c.) immunized with $1\times10^4\text{ PFU}$ of E218A, and PBS group was set as control. Sera were collected at 2 and 4 weeks after immunization for further assay. Four weeks after immunization, the mice in each group were i.p. challenged with lethal dose of JEV strains of SX-06 (genotype I) and SA14 (genotype III), respectively. The mortality was then monitored for at least 15 days.

A129 mice on the 129/SvEv genetic background were obtained from B&K Universal Ltd., and bred in a specific-pathogen-free facility. Groups of 3-week-old 129 and A129 mice were i.p. injected with $5\times10^7\text{ PFU}$ of WT and E218A, respectively, and then monitored daily for 15 days to assess morbidity and mortality. Survival analyses were performed by log-rank tests using GraphPad Prism software 5.0. Average surviving time (AST) were calculated and analyzed by student’s t-test.

**IgG and Neutralizing antibody assay.** IFA was used to measure the IgG antibodies titer against JEV in the sera of immunized mice as previously described (30). Briefly, two-fold serially diluted sera were incubated at $37^\circ\text{C}$ for 1 h on the prepared JEV antigenic slide. After that, FITC-conjugated goat anti-mouse IgG in 0.02% Evans blue dilutions was added and incubated at $37^\circ\text{C}$ for another 30 min. Finally, positive cells were detected using a fluorescent microscope.

The neutralizing antibodies titer against JEV in the immunized mice was measured by standard plaque reduction neutralization test (PRNT). Briefly, serial two-fold
dilutions of sera samples were mixed with equal volumes of JEV suspension, and inoculated in a 12-well plate containing confluent BHK-21 cells. The plates were then overlaid with 1% agarose-containing medium and incubated at 37 °C for 3 days for plaque formation and counting. The PRNT_{50} were then calculated as previously described (7).

**Splenocytes proliferation and cytokine assay.** For proliferation assay, spleens from immunized and control mice were aseptically harvested, crushed with sterile glass crusher in RPMI-1640 (Sigma) and filtered with the sterile nylon cell strainer (BD Falcon) to prepare the single cell suspension. Splenocytes suspension (2×10^5) were then plated in a 96-well plate in triplicate and were stimulated with 100 μl of heat-inactivated JEV (2.5 μg/ml) for 96 h, and Concanavalin A (Con A) (Sigma) was used as control. The splenocyte proliferation was determined with MTS method using CellTiter96® Non-Radioactive Cell Proliferation Assay kit (Promega) and the stimulation index (SI) was calculated as mean OD values of stimulated cells/mean OD values of unstimulated cells, and SI \( \geq 2 \) was considered significant. IFN-γ in the culture supernatants was assayed with the mouse IFN-γ ELISA kit (Excell).

**IFN pretreatment and IFIT overexpression.** BHK-21 cells grown in 96-well plates were infected at an MOI of 5 with WT or E218A for 1 h at 37°C. Cells were then treated with various dose of IFN-αA/D (Sigma) (10, 100 or 500U/ml) and incubated for additional 48 h. Then the supernatants were collected and virus titers were determined by plaque assay in BHK-21 cells. Cell viability was determined by MTS assay (Promega) according to the manufacturer’s instructions.
Human IFIT expression plasmids were kindly provided by Dr. Pichlmair A (23).

HEK293 cells were transfected with equal amount of plasmids IFIT1, 2, 3, and 5 using Lipo2000 according to manufacturers’ protocol. After 24 hours of incubation cells were infected with the WT and mutant JEV at an MOI of 1. The viral titers in the supernatant were then assayed at 24, 48, and 72 h post infection by plaque assay.

**Statistic analysis.** The significance between survival curves from each group was analysed by Kaplan-Meier survival analysis with log-rank tests with GraphPad Prism software 5.0. Average results were obtained from at least three independent experiments, and Student’s t-test was used to determine whether a significant difference (P<0.05) existed.

**RESULTS**

**N-7 and 2’-O methylations of WT and mutant JEV MTase.** Although the MTase catalytic K-D-K-E tetrad is highly conserved among flaviviruses, the methylation of JEV MTase has not been experimentally demonstrated. Sequence alignment among various members of flavivirus (data not shown) indicates that amino acid E218 represents the glutamic acid within the K-D-K-E tetrad of the JEV MTase domain. We prepared recombinant WT and E218A mutant MTase proteins of JEV (representing the N-terminal 300 amino acids of NS5). SDS-PAGE analysis showed that the purified proteins were >95% pure with the expected molecular mass of 35 kD (Fig. 1A). For detection of N-7 methylation (GpppA→m7GpppA), substrate G*pppA-RNA
(representing the first 190 nucleotides of 5′-end of the JEV genome) was incubated with
the recombinant MTases in the presence of SAM. The reaction products were digested
with nuclease P1 and analysed on a TLC plate. We found the optimal condition for N-7
methylation at pH 6.0 (data not shown) and 300 mM NaCl (Fig. 1B). The E218A
substitution reduced N-7 methylation to 15% of the WT level (Fig. 1C). For detection
of 2′-O methylation, we measured the m7GpppA→m7GpppAm conversion. The
E218A substitution completely knocked out the 2′-O methylation (Fig. 1D),
demonstrating that E218 of the K-D-K-E tetrad is essential for the 2′-O methylation.

**Nuclease P1 from different vendors affects the migration of m7GpppAm molecule on TLC plate.** Contradictory results were previously reported on the
migration position of m7GpppAm on TLC plates. Some groups found that m7GpppAm
migrated faster than m7GpppA (1, 3, 25), whereas other groups showed that
m7GpppAm migrated slower than m7GpppA (19). As shown in Fig. 1E, after the 2′-O
methylation reaction (m7GpppA→m7GpppAm) was cleaved with the nuclease P1
purchased from Sigma-Aldrich (Catalog number N8630), the m7GpppAm product
migrated faster than m7GpppA. In contrast, after the reaction was cleaved with the
nuclease P1 purchased from US Biological (Catalog number N7000), the m7GpppAm
product migrated slower than m7GpppA. For this experiment, we used the WT JEV
MTase as well as Vaccinia virus VP39 (a well-characterized 2′-O MTase as a positive
control). We currently don’t know what component(s) in the nuclease P1 reaction from
the two vendors caused the difference in migration.

**Recovery and characterization of the 2′-O MTase mutant JEV.** To generate a 2′-O
MTase mutant JEV, E218A mutation was introduced into the full-length infectious clone of JEV pAJE70 (29). Transfection of BHK-21 cells with genome-length RNAs generated equivalent numbers of viral E protein-positive cells between the WT and E218A RNAs (Fig. 2A). Genomic sequencing confirmed that the designed mutation E218A was retained in the recovered virus and no additional mutations were introduced (data not shown). One-step growth curves in mammalian (BHK-21 and Vero) and mosquito (C6/36) cells showed that the mutant virus replicated slightly slower than the WT virus at 24 and 48 h, but peaked at similar levels at 72 h post-infection (Fig. 2B). Interestingly, the E218A virus exhibited smaller plaque morphology compared to the WT virus (Fig. 2C). Continuous culturing of the mutant virus on Vero cells for ten rounds (3-4 days per round) did not change its small plaque morphology (Fig. 2C). Genomic sequencing of the passage 10 virus showed that the engineered E218A change was retained without any extra mutation (data not shown). The results indicate that the 2'-O MTase mutant JEV is highly replicative and genetically stable in cell culture.

2'-O MTase mutant JEV is highly attenuated in mice. We compared the neuroinvasiveness of the WT and E218A viruses in mice. Groups of 3-week-old Balb/C mice were i.p. injected with 4×10^7 PFU of WT or E218A JEV; the mortality of the infected mice was monitored for 2 weeks. The WT-infected mice all died within 9 days, whereas the E218A-infected mice all survived with no neurological symptoms (Fig. 3A). Viremia was detected at day 1 post-infection in the WT-infected mice, whereas no viremia (i.e., below the detection limit of plaque assay) was observed in the E218A-infected mice (Fig. 3B). The WT virus was detected in mice brains at days 1, 3,
5, and 7 post-infection; on the contrary, the mutant virus could only be detected in brains at days 3 and 5 post-infection, and the titers were much lower than those from WT group (Fig. 3C). These results demonstrate that the 2'-O MTase mutant JEV significantly reduces its neuroinvasiveness in mice.

We also compared the neurovirulence of the WT and E218A viruses in mice. Mice were i.c. inoculated with serial dilutions of the WT or mutant viruses. As shown in Table 1, the mutant virus E218A was significantly attenuated: the LD_{50} of E218A was about 24-fold higher than that of the WT virus. The AST (average surviving time) of the mutant virus-inoculated mice for each dose was significantly longer than that of WT virus-infected mice. Collectively, these results demonstrate that the 2'-O MTase mutant of JEV is attenuated in mice. In addition, we sequenced the mutant viruses recovered from the dead mice after i.c. inoculation of high doses (≥ 1×10^{1.9} PFU); the engineered E218A mutation was retained from all samples with no other nucleotide changes detected. This result demonstrates the in vivo stability of the E218A mutant virus.

The 2'-O MTase mutant virus induces protective immune response in mice. The immunogenicity of the 2'-O MTase mutant virus was evaluated in mice. JEV-specific IgG and neutralizing antibodies were assayed by IFA and PRNT at 14 and 28 days post immunization. A single-dose immunization with 1×10^{4} PFU of E218A induced robust IgG and neutralizing antibodies (Fig. 4A); the geometric mean titer (GMT) of neutralizing antibody against JEV reached 97.4 at 28 days post immunization (Fig. 4B). As expected, no JEV-specific antibodies were detected in the sera collected prior
Cellular immunity to JEV was determined by splenocytes proliferative response and IFN-γ production in splenocytes from the vaccinated mice on day ? post infection. MTS assay showed that the SI value (2.61 ± 0.21) of the E218A virus-immunized mice was significantly higher than that of the control groups (1.30 ± 0.09) (Fig. 4C). IFN-γ production in splenocytes from the E218A virus-immunized mice was significantly higher than that of the control groups (261.43 ± 16.94 v.s. 42.62±5.47) under the stimulation with JEV (Fig. 4D). Together, these results clearly demonstrate that a single-dose vaccination of the E218A virus induces robust humoral and cellular immune response in mice.

Next, we challenged the immunized mice with lethal doses of JEV strains SX-06 and SA14, representative of genotype I and genotype III of JEV, respectively (Fig. 4E). All the PBS-immunized mice died within 6-10 days after the challenge; whereas all the E218A virus-immunized mice survived against the lethal challenges, and none of them developed any clinical manifestations. Thus, a single dose of JEV 2'-O MTase mutant immunization provides full protection against lethal challenge of different JEV genotypes.

2'-O MTase mutant virus shows enhanced sensitivity to IFN and IFITs. To explore the molecular mechanism of attenuation for 2'-O MTase mutant JEV, we compared the virulence of the WT and mutant viruses in mice deficient in type I IFN receptors (A129 mice) and its parental 129 mice. A129 and 129 mice were i.p. challenged with the WT and mutant JEV. The results showed that even high dose of
5×10^7 PFU of the E218A virus failed to kill any 129 mice (Fig. 5A), which was in agreement with the results from Balb/C mice (Fig. 3A). However, both the WT and E218A showed 100% mortality within 4 days in the A129 mice; only a slightly delay of death was observed in the E218A virus-infected mice compared with the WT virus (Fig. 5B), indicating the critical role of IFN signaling for the attenuation phenotype of the mutant virus.

Next, we compared the sensitivity of the WT and mutant viruses to IFN-α pretreatment in cell culture. The result showed that the mutant virus was more sensitive to the antiviral effect of varying concentrations of IFN-α than the WT did (Fig. 5C). Moreover, IFN-α treatment strongly inhibited the yield of E218A in BHK-21 cells in a dose-dependent manner, whereas the WT virus was only slightly impaired by the same dose of IFN-α treatment (Fig. 5D).

Finally, we compared the antiviral effect of human IFIT1, 2, 3, or 5 on the WT and mutant viruses. HEK293 cells transgenically expressing individual IFIT were infected with the WT or mutant virus; the viral titers in supernatants were determined at the indicated times post infection. The over-expression of IFIT1, 2, 3, and 5 significantly inhibited the production of the mutant virus at 72 h post infection, whereas none IFITs suppressed the production of the WT virus (Fig. 5E). As a control, Western blotting analysis showed equal levels of IFIT1, 2, 3, and 5 protein expressions in the transfected HEK293 cells (data not shown). Taken together, we conclude that the \textit{in vivo} attenuation of the 2''-O MTase mutant JEV is attributed to the enhanced sensitivity to the antiviral action of IFN and IFIT proteins.
DISCUSSION

This study aims to test the hypothesis of using 2'-O methylation-defective virus as a vaccine approach. Using JEV as a model, we functionally analyze the E218A mutation of the viral NS5 protein in cap methylation, viral replication, mouse virulence, and evasion of innate immune response. We chose JEV as the model to test the 2'-O MTase vaccine approach because of the availability of a good mouse model for this virus. In agreement with other MTase results, the E218A mutation of JEV MTase K-D-K-E tetrad completely abolished the 2'-O methylation activity while retained the N-7 methylation activity. However, the effect of the E218A mutation on N-7 methylation is more significant in JEV MTase (15% of the WT activity) than those in WNV MTase [76-92% of the WT activity; (33)] and DENV MTase [59% of the WT activity; (9)]. These results indicate the plasticity of the role of MTase K-D-K-E tetrad in the methylation activities among various flaviviruses.

We showed that recombinant JEV lacking 2'-O MTase activity was replicative, but highly sensitive to the antiviral effects of IFN and IFITs. Compared with the WT JEV, cells infected with the mutant virus did not induce higher levels of IFN production (Data not shown). The latter result is similar to that observed for the 2'-O MTase mutant WNV (5, 34), but different from that observed for the 2'-O MTase mutant MHV virus [which showed enhanced IFN production than the WT virus; (34)]. However, the 2'-O MTase mutant JEV was sensitively inhibited by all four tested human IFITs; whereas the 2'-O MTase mutant WNV was only inhibited by mouse
IFIT-2, not IFIT-1, -3, or -5 (5). This different sensitivity to IFITs between the mutant JEV and WNV could be due to different species of IFITs used in the two studies. Human IFITs are critical for the inhibition of viral infections (11, 12, 28), but the functions of these IFITs are only partially understood. Nevertheless, the mutant 2'-O-MTase JEV showed reduced virulence in mice. Furthermore, mice immunized with a single dose of the mutant JEV were completely protected against lethal challenge of virulent JEV strains. These results demonstrate the potential of this rationally designed 2'-O MTase mutant virus for further development as a vaccine approach.

Our results support the concept that an attenuated virus could be rationally designed by altering the ability of virus to antagonize innate immunity (26). Previously, Talon and co-workers proposed and tested this concept by reducing the ability of influenza virus to antagonize type I IFN response (26). Non-structural protein1 (NS1) of influenza A and B viruses antagonizes the IFN response following infection and contributes to the virulence (14); viruses partial deletions of NS1 are attenuated, yet induce a protective immune response in mice (26).

A live JE vaccine SA14-14-2 derived from continual passaging in cells and animals have been widely used in Asia and saved millions of lives. Currently, the live SA14-14-2 vaccine has been licensed in ten Asian countries, and the primary hamster kidney cells was approved for vaccine production by World Health Organization (30). However, the SA14-14-2 vaccine has not yet been approved for use in the first world markets. With the development of reverse genetics of flavivirus (20, 24, 31), rational design of recombinant live attenuated JEV vaccine has become possible. A novel live
attenuated JEV vaccine IMOJEV using the yellow fever 17D virus as a backbone was recently licensed in Australia and Thailand (6, 15). The results presented in this study demonstrate that the JEV 2'-O MTase mutant E218A could potentially serve as a novel live JEV vaccine candidate.

The 2'-O MTase mutant vaccine has several advantages over the licensed JEV vaccines. First, E218A showed ideal attenuation profile in cells and animal. It completely lost its neuroinvasiveness (Fig. 3A and B). The E218A mutant virus was stable; no second-site mutation was detected even after ten passages (>30 days) in Vero cells. The engineered mutation was also retained in the virus recovered from the mice died of high dose i.e. inoculation of the E218A virus, demonstrating the in vivo stability of the mutant virus. Second, the E218A virus exhibited an ideal immunogenicity; a single immunization of E218A induced high titers of neutralizing antibodies (GMT=97.4) as well as robust cellular immune response in mice (Fig. 4).

Previous clinical trial and animal experiments of JEV vaccine showed that neutralization antibody titer over 10 was protective (27). Third, the 2'-O MTase mutant JEV attenuated due to the single E218A mutation in NS5 protein via a defined mechanism in association with host IFN response. Previous studies based on SA14-14-2 or other attenuated strains indicate the critical role of several mutations in the E protein in governing the attenuation phenotype (2, 18, 20, 21, 29, 32). However, these mutations are within the major protective antigen E protein and could alter the native antibody repertoire, leading to a high risk of emergence of neutralization escape mutant. For the current 2'-O MTase approach, we could improve the safety of
the 2′-O MTase mutant vaccine by engineering double or triple mutations within the K-D-K-E active site of the JEV MTase. This would minimize the reversion of the mutant MTase to the WT sequence.

Overall, by *in vitro* and *in vivo* charactering the 2′-O methylation of JEV MTase, we provide various lines of evidence for the highly attenuated recombinant JEV mutant E218A as a potential JEV live vaccine approach. This vaccine approach warrants further development, especially considering the great need for a low-cost but high-efficacy vaccine for a neglected disease in developing countries. Moreover, this rational design approach can be readily applicable to other viruses with defined 2′-O MTase activity for potential vaccine development.

ACKNOWLEDGEMENTS

We thank Dr. Andreas Pichlmair (CEMM, Austria) for providing the human IFIT plasmids and Prof. Yongxin Yu (NIFDC, Beijing) for helpful discussions. This work was supported by the Basic Research Project of China (No.2012CB518904), and National Natural Science Foundation of China (No.81101243 and No.31270974). PYS group is partially supported by the TCR flagship “STOP Dengue” program from National Medical Research Council in Singapore. CFQ was supported by the Beijing Nova Program of Science and Technology (No.2010B041).
REFERENCES


24


FIGURE LEGENDS

FIG. 1. N-7 and 2'-O cap methylations of the viral RNA by JEV MTase. (A) Analysis of recombinant JEV MTase proteins in 12% SDS-PAGE, the size (Kilodalton) of protein marker is labelled on the left. (B) N-7 methylation. N-7 methylation assays were performed using substrate G*pppA-RNA, the reaction mixtures were digested with nuclease P1 (purchased from US Biological) and analysed on TLC plates. The conversion of G*pppA-RNA to m7G*pppA-RNA was quantified using a PhosphorImager. 33P-labeled m7G*pppA or G*pppA marker is indicated on top of the TLC plate. The optimal concentration of NaCl was determined by titration (B). Relative activities are presented using the optimal level as 100%. (C) N-7 activity analysis of mutant E218A MTase. The methylation efficiency of the E218A was compared with that of the WT MTase (set at 100%). Average results from three independent experiments are shown. (D) Analysis of 2'-O methylation activity of the E218A MTase. 2'-O methylation assays were performed using m7G*pppA-RNA substrate. The reaction mixtures were incubated at 23°C for 15 min, digested with nuclease P1 (US Biological) and analysed on TLC plates. 33P-labeled cap structures (m7G*pppA or G*pppA) are indicated on the bottom of the TLC plate. The position of the origin and the migration positions of the G*pppA, m7G*pppA, and m7G*pppAm molecules are shown to the right of the TLC plate. The methylation efficiency of the E218A was compared with that of the WT MTase (set at 100%). Average results from three independent experiments are shown. (E) Effect of nuclease P1 from two different vendors (indicated) on the migration of the m7G*pppAm. 2'-O
methylation assays were the same as (D) except that the reaction was done at 23°C for 30 min (JEV MTase) or 37°C for 30 min (VP39). Half of the samples were digested with nuclease P1 in 20 mM Tris-HCl (pH 7.5) buffer, and the other half of the samples were digested with nuclease P1 in the same buffer, then analysed on TLC plates. 33P-labeled cap structures (m7G*pppA or G*pppA) are indicated on the bottom of the TLC plate. The position of the origin and the migration positions of the G*pppA, m7G*pppA, and m7G*pppAm molecules are shown to the left of the TLC plate.

FIG. 2. Recovery and characterization of JEV MTase mutant virus. (A) BHK-21 cells were transfected with equal amounts of RNA transcripts from pAJE70 and pAJE70-E218A, and subjected to IFA using anti-JEV E protein mAb 4D5 at the indicated time post transfection. (B) Growth kinetics in different cell lines. BHK-21, Vero and C6/36 cells were infected with WT and E218A at an MOI of 1. Viral titers were measured at indicated times using standard plaque assays in BHK-21 cells. (C) Plaque morphology and genetic stability of E218A mutant. E218A recovered from RNA-transfected cells (passage 0), as well as passaging on Vero cells for 5 and 10 rounds (passage 5 and 10) were analysed by standard plaque assays and compared with the WT virus.

FIG. 3. JEV 2'-O MTase mutant is highly attenuated in mice. (A) Neuroinvasiveness tests for WT and E218A mutant virus in mice. Groups of
3-week-old Balb/C mice (n=6) were i.p. injected with $4 \times 10^7$ PFU of WT and E218A. The mortality was monitored for 15 days or till death. The significance between survival curves from each group was analysed by Kaplan-Meier survival analysis with log-rank tests. Viral loads in mouse sera (B) and brain tissue (C) were measured by plaque assay at the indicated time post infection. Dotted lines represent limits of detection.

**FIG. 4. JEV 2'-O MTase mutant is immunogenic and protective in mice.**

Mice immunized with $1 \times 10^4$ PFU of E218A or control group were bled on 14 and 28 days post immunization. The titers of IgG antibody (A) and neutralization antibody (B) were determined by IFA and PRNT, respectively. JEV-specific cellular immune response induced by E218A immunization was assayed by splenocytes proliferation assay (C) and IFN-$\gamma$ production assay (D). On day ? post infection, the spleens from immunized mice of various experimental groups were separated and the proliferation was tested in presence of inactivated JEV or the positive control Con A. The culture supernatants were collected after 72 h of stimulation with inactivated JEV and Con A for IFN-$\gamma$ assay. Challenge experiments were performed with JEV strains SA14 and SX06 (E). Groups of mice (n=10) immunized with E218A or PBS were challenged with $1 \times 10^8$ PFU of SA14 and SX06. The mortality was recorded daily, and the survival curve from each group was analysed by Kaplan-Meier survival analysis with log-rank tests.
FIG. 5. JEV 2'-O MTase mutant shows enhanced sensitivity to IFN and IFITs.

Groups of 3-week-old 129 mice (A) and A129 mice (B) were i.p. injected with $5 \times 10^7$ PFU of WT or E218A. The mortality was monitored for 15 days or till death. BHK-21 cells in 96-well plate were infected with the WT or E218A mutant virus at an MOI of 5 for 1 h, followed by treatment with various doses of IFN-αA/D (10, 100 or 500 U/ml). MTS assay (C) and plaque assay (D) were performed 48 h post infection. HEK293 cells were transfected with equal amount of plasmids IFIT1, 2, 3, and 5 using Lipo2000 following by infection with WT and E218A at an MOI of 1. The viral titers in the supernatant were then assayed at the indicated times post infection by plaque assay.
Table 1. Comparison of neurovirulence between the WT and MTase E218A mutant viruses in mice*

<table>
<thead>
<tr>
<th>Virus</th>
<th>Dose (log_{10}PFU)</th>
<th>No. dead/ No. inoculated (% mortality)</th>
<th>LD_{50} (PFU)</th>
<th>AST (range, d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>3.9</td>
<td>8/8 (100)</td>
<td>7.9</td>
<td>4.6 (4-6)</td>
</tr>
<tr>
<td></td>
<td>2.9</td>
<td>8/8 (100)</td>
<td></td>
<td>4.9 (4-6)</td>
</tr>
<tr>
<td></td>
<td>1.9</td>
<td>8/8 (100)</td>
<td></td>
<td>8.1 (7-9)</td>
</tr>
<tr>
<td></td>
<td>0.9</td>
<td>4/8 (50)</td>
<td></td>
<td>12.0 (7-15)</td>
</tr>
<tr>
<td>E218A</td>
<td>3.9</td>
<td>8/8 (100)</td>
<td>188.4</td>
<td>8.0 (6-10)</td>
</tr>
<tr>
<td></td>
<td>2.9</td>
<td>8/8 (100)</td>
<td></td>
<td>8.8 (7-11)</td>
</tr>
<tr>
<td></td>
<td>1.9</td>
<td>2/10 (20)</td>
<td></td>
<td>12.75 (10-15)</td>
</tr>
<tr>
<td></td>
<td>0.9</td>
<td>0/8 (0)</td>
<td></td>
<td>15 (15)</td>
</tr>
</tbody>
</table>

*Groups of 3-week-old Balb/C mice were i.c. injected with varying doses of WT and E218A mutant viruses. The number of surviving mice was recorded daily.